|
 |
Volume 3, Number 2 (February 2006) | |||||
Letter from the Editor |
|||||
66 |
Cancer genetics, Medicare maze, and more… Pennsylvania Hospital, Philadelphia, PA Increasingly, community oncology practices are offering genetic testing for at-risk patients. Although it is clear that clinicians must discuss the implications of a patient’s test results with that patient, what is not so clear is the obligation to discuss those same results with the patient’s at-risk relatives. A key question: how can you protect your patient’s right to privacy at the same time you protect yourself from potential lawsuits? On another critical topic, we look at Medicare Part D, as well as treating hypertension in oncology patients, and lenalidomide in patients with myelodysplastic syndromes.
|
||||
Community Translations |
|||||
71 |
Lenalidomide in myelodysplastic syndromes Lenalidomide is a thalidomide analog that was just approved for use in treating transfusion-dependent patients with myelodysplastic syndromes. An orphan drug with fast-track designation from the FDA, this agent is also being investigated for use in multiple myeloma and various solid tumors.
|
||||
Community Dialogue |
|||||
75 |
Joining forces to beat multiple myeloma The aim of the Consortium is to coordinate and speed new drug research among institutions, using an innovative model. Ms. Giusti talks about the Consortium's progress, its tissue and information banks, and the role of community practices.
|
||||
Original Contribution |
|||||
90 |
Bevacizumab-related toxicities: association of hypertension and proteinuria City of Hope Medical Group, Pasadena, CA, and Wilshire Oncology Medical Group, La Verne, CA Bevacizumab is generally well tolerated, but its use has been associated with hypertension, proteinuria, and other toxicities. Optimal management of "benign toxicity syndrome" should include early intervention with antihypertensive drugs protective against proteinuria and nephropathy. Prompt intervention before hypertension or proteinuria becomes severe may permit prolonged therapy with bevacizumab and a greater cumulative dose, potentially improving survival.
|
||||
Managing Side Effects |
|||||
94 |
Hypertension therapy for the oncology patient Pennsylvania Hospital, Philadelphia, PA As many as 50% of cancer patients may have hypertension, and certain therapies such as bevacizumab may cause or exacerbate the condition. With three case histories, this article reviews the new types of medications that deal with hypertension and how to choose drug treatment according to the mechanism of action, side-effect profile, drug interactions, and "compelling indications."
|
||||
Controversies in Patient Management |
|||||
100 |
Legal considerations in clinical cancer genetics Humanities and Law, Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE, and Hubert H. Humphrey Cancer Center, Robbinsdale, MN Informed consent for cancer susceptibility testing should include a discussion of the potential importance of test results to the healthcare planning of other family members. Physicians clearly have a duty to inform the patient about the results. But what about warning at-risk relatives? How to deflect potential lawsuits when the duty to warn is not yet settled.
|
||||
Challenging Cases/Rare Cancers |
|||||
106 |
Vulvar metastasis from breast cancer Southern Kentucky Hematology & Oncology, PLLC, Somerset, KY Malignant tumors of the vulva are rare, with only a few reported cases appearing in the literature. The authors present a case in a 57-year-old woman with breast cancer. A high level of suspicion and further workup are needed to differentiate primary malignancy of the vulva from metastatic disease or treatable cancers such as breast cancer.
|
||||
Brief Communications |
|||||
69 |
Mantle cell lymphoma of the prostate Ireland Cancer Center, University Hospitals Health Care System, Cleveland, OH
|
||||
Meetings Highlights |
|||||
85 |
Research highlights for hematologic cancers
|
||||
86 |
Advances in breast cancer treatment
|
||||
Washington Update |
|||||
111 |
Medicare maze, Part D Oncologists are bracing themselves and patients are frustrated.
|
||||
112 |
Patient handout: Deciding on your Medicare prescription drug coverage
|
||||
Technology |
|||||
113 |
Podcasting: your information pipeline With podcasts, you can stay current and offer your patients helpful information.
| ||||
Legal Matters |
|||||
114 |
Ask your lawyer How to deal with a drug-abusing employee.
| ||||
Book Review |
|||||
116 |
A reflection of progress and hope Reviewed by Myrna R. Rosenfeld, MD, PhD, Department of Neurology, University of Pennsylvania, Philadelphia, PA
|
||||
© 2006 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher. |
|||||
42 kb